ß-Arrestin Structure and Function {#sec1}
=================================

The arrestin family of proteins includes four members and a variety of splice variants. There are two visual arrestins, found only in the retina ([@ref89]), and two ubiquitously expressed arrestins named ß-arrestin1 (arrestin-2) ([@ref52]) and ß-arrestin2 (arrestin-3) ([@ref3]). The beta prefix is because their first documented receptor substrate was the ß~2~-adrenergic receptor (ß~2~AR) and the "arrestin" term was because their major function is in terminating (or 'arresting') signaling *via* G proteins ([@ref6]). ß-arrestin proteins have functional and structural domains that allow them to bind to receptors as well as biochemical intermediates, events that are key to their function ([@ref82]; [@ref68]). Although ß-arrestins interact with several different types of cell surface receptors ([@ref82]), this review will focus on their role in modulating heptahelical receptors.

Heptahelical receptors, also known as seven-transmembrane receptors (7TMRs), are characterized by seven membrane-spanning domains and constitute the largest family of cell surface receptors known to date. The 7TMR superfamily is responsible for transducing a wide variety of extracellular signals into intracellular functions. More than three decades ago, it was shown that ligand activation of 7TMRs resulted in intracellular signaling through receptor coupling to heterotrimeric guanine nucleotide or G proteins ([@ref77]; [@ref62]). Thus, 7TMRs are more commonly known as G protein-coupled receptors (GPCRs). Therapeutically, these GPCRs are a very important class of receptor since they mediate almost all physiological processes, and their signaling is the target of roughly 40% of all prescribed drugs ([@ref113]).

Numerous *in vitro* studies show that ß-arrestins terminate G protein-mediated cell signaling by translocating and binding to GRK-phosphorylated serine and threonine residues in the GPCR third intracellular loop or C terminal tail. Once bound, ß-arrestins sterically prevent further receptor-G-protein coupling ([@ref6]). This termination of G protein signaling is the canonical role for ß-arrestin. Later it was found that in addition to terminating G protein signaling, ß-arrestins also initiate ß-arrestin-dependent cell signaling by acting as scaffold proteins that couple the receptor to a growing list of signaling intermediates, many of which are kinases ([@ref54]; [@ref47]). This receptor-ß-arrestin-kinase complex is internalized *via* endocytic vesicles thereby becoming an intracellular "signalosome". Recently, this concept has been broadened to show that endocytic vesicles lacking the receptor, but containing receptor-activated ß-arrestin, can also internalize and activate cell signaling ([@ref31]). In this newly discovered mechanism, the interaction of translocated ß-arrestin with the GPCR is temporary but sufficient to change the conformation of ß-arrestin thereby activating it. The activated ß-arrestin is able to bind to membrane phosphoinositides that link it to the cell membrane for endocytosis into signaling vesicles.

Internalization of signaling vesicles is mediated by interactions between the C terminal tail of GPCR-activated ß-arrestin and the cell membrane endocytic proteins, clathrin and AP-2 (adapter protein-2) ([@ref36]; [@ref46]). This adaptor function of ß-arrestin is crucially important to not only receptor internalization but also ß-arrestin-dependent signaling. ß-arrestins bind to E3 ubiquitin ligases and deubiquitinases that direct GPCR-ß-arrestin vesicles to degradative or recycling pathways within the cell, thus modulating receptor cell surface expression ([@ref83]; [@ref81]). This trafficking function of ß-arrestins is yet another way by which these multifunctional proteins modulate GPCR signaling and cellular responses. Furthermore, ß-arrestins are also able to dampen G protein-mediated second messenger generation (ie., cAMP) by binding to second-messenger degrading enzymes, such as phosphodiesterases (PDE), and translocating them to the ligand-activated receptor ([@ref67]). Taken together, ß-arrestins are the predominant modulators of GPCR signaling. The activated conformation, and thus function, of ß-arrestin is influenced by the GPCR type to which it has translocated as well as the conformation of the activated receptor (reviewed in ([@ref68])). The ß-arrestins are structurally flexible proteins which allow them to bind to a broad spectrum of partners and mediate a wide variety of functions ([@ref79]). Because biased ligands influence different conformational states of GPCRs, they indirectly influence ß-arrestin-dependent signaling, making them key therapeutic molecules. Additionally, biasing the structure/function of ß-arrestins to impact signal transduction has also been proposed as a novel therapeutic strategy ([@ref18]). Our review does not focus on the finer points of structural data and complex equilibria of conformational states as these have recently been the topics of several excellent reviews ([@ref68]; [@ref79]; [@ref18]).

With the development of mice deficient in either ß-arrestin1 or ß-arrestin2 ([@ref21]; [@ref11]), evidence supported the *in vitro* experimental conclusions that ß-arrestins play an important role in regulating normal physiological and pathophysiological responses. Despite the lethality resulting from elimination of both ß-arrestins, single ß-arrestin-knockout (ß-arrestin-KO) mice are quite normal and perturbations of homeostasis are often required to observe an effect of the absence of ß-arrestin expression.

The first published study examining normal physiologic responses in ß-arrestin2-KO mice involved exogenous opioid administration as the homeostatic perturbation ([@ref10]). Bohn et al. showed the immediate anti-nociceptive effect of opioids was enhanced in ß-arrestin2-KO mice, and the negative side effects of opioids, such as respiratory depression and diminished gastrointestinal motility, were reduced. Although signaling pathways were not measured, the absence of depressed respiration and gut motility in ß-arrestin2-KO mice suggested that ß-arrestin-dependent signaling promoted those responses. Conversely, the enhanced analgesia pointed to a physiologically relevant role for ß-arrestin2-mediated desensitization of opioid receptor G protein-dependent signaling in the mechanism of pain relief.

The first study demonstrating a role for ß-arrestin in disease pathogenesis used a murine model of asthma ([@ref109]). This study, and our subsequent work, showed ß-arrestin2-dependent phospho-p38 mitogen-activated protein kinase (Pp38) signaling to be crucial for T helper type 2 (Th2) cell chemotaxis ([@ref49]). Furthermore, protection from developing the asthma phenotype in ß-arrestin2-KO mice is associated with significant inhibition of CD4+ Th2 cell chemotaxis to the lung and marked reductions in airway epithelial cell mucin secretion and airway inflammation ([@ref109]).

ß-Arrestin Modulation of Physiology and Pathophysiology {#sec2}
=======================================================

ß-arrestins trigger physiological responses through scaffolding of cell signaling proteins such as extracellular signal-regulated kinases 1 and 2 (ERK1/2), proto-oncogene tyrosine protein kinase Src (c-Src family tyrosine kinases), phosphoinositide 3-kinases, protein kinase B (AKT), c-Jun N-terminal kinases (JNK3) and elements of nuclear factor κb (NF κb) ([@ref82]; [@ref68]).

Although convenient to characterize GPCR signaling as two distinct signaling pathways, one that is G-protein dependent/ß-arrestin-independent and the other that is ß-arrestin-dependent/G protein-independent, the reality is more complex. We recently showed that P-p38 signaling, and associated chemotaxis, of T helper type 2 cells is partially dependent on ß-arrestin2 and that this ß-arrestin2-dependent signaling is downstream of Gαi ([@ref49]). In that paper, we described the dual chemotaxis signaling pathways as ß-arrestin dependent and ß-arrestin independent; of course, both pathways were G protein-dependent. Work from [@ref39] has provided further evidence of G protein-dependency for ß-arrestin-mediated signaling. They used groundbreaking CRISPR/Cas9 technology to produce HEK293 cells that either do not express arrestins or lack all G proteins except Gαi, which was pharmacologically inhibited using pertussis toxin (PTX). Using these cell lines, dubbed "zero arrestin" and "zero functional G," respectively, they showed that ß-arrestin-dependent signaling is downstream of G proteins for several GPCRs including some canonical receptors where this was not previously believed to be the case. Although the receptor and cell types were limited in their study, the results have important implications for drug discovery and suggest G proteins as the "genuine drivers of GPCR-mediated signal transduction." However, whether or not ß-arrestin is a signaling molecule or a scaffolding protein, or is dependent or independent of G protein signaling, is immaterial to its extremely important regulation of cellular function ([@ref41]). Thus, the lexicon used to describe GPCR signaling could benefit from expansion and clarification where descriptors of both the G protein and ß-arrestin involvement are listed (G protein-dependent/independent and ß-arrestin-dependent/independent).

As predicted by experimental findings, the ß-arrestin-dependent signaling pathway, like its G protein (ß-arrestin-independent) counterpart, regulates a wide variety of important cellular responses including cell development, growth and survival, immune cell function, protein translation, and neuronal signaling ([@ref40]). The ability of ß-arrestins to desensitize G protein-dependent and mediate ß-arrestin-dependent GPCR signaling pathways uniquely positions these proteins to exert a major influence on physiology and pathophysiology.

The discovery that a single GPCR subtype can couple to different transduction proteins and produce multiple cellular responses has led to development of ligands that can preferentially "bias" the receptor toward one pathway. Some of these "biased ligands" preferentially target the ß-arrestin pathways (by either activation or inhibition) and have shown promise in drug development. These advances will be discussed in the section titled *ß-arrestin versus G-protein signaling in disease*.

ß-Arrestin Expression in Disease {#sec52}
================================

Consistent with the broad range of physiological processes modulated by ß-arrestins, the upregulation of ß-arrestin expression is associated with many diseases. Whether or not changes in expression are adaptive or maladaptive remain to be determined. For example, in a mouse model of cardiac dysfunction, enhanced cardiac ß-arrestin2 expression mitigated adverse cardiac remodeling ([@ref38]); whereas in murine asthma, T cell and lung structural cell overexpression of ß-arrestin2 is maladaptive ([@ref109]; [@ref17]; [@ref80]). Elevated ß-arrestin expression and concomitant anti-apoptotic effect is associated with fibrotic diseases (reviewed in ([@ref40]) and in multiple sclerosis (MS) where CD4+ T cells from patients have a higher expression of ß-arrestin1 ([@ref85]). These results implicate increased ß-arrestin1 as mediating the survival of CD4+ T and promoting disease pathogenesis ([@ref85]). Another study reported similar upregulation of ß-arrestin1 expression in the brains of MS patients and in an animal model of experimental autoimmune encephalomyelitis (EAE), a commonly used model of human inflammatory demyelinating disease ([@ref101]). Other diseases that implicate ß-arrestin in pathophysiology include Alzheimer's disease (AD), cystic fibrosis (CF) and meningitis. In AD, brain protein and mRNA levels of ß-arrestin1 and ß-arrestin2 are elevated ([@ref50]; [@ref42]). In CF, patient nasal epithelial cells, as well as CF model cells, overexpress ß-arrestin2 ([@ref56]). With respect to immunity, expression of ß-arrestin2 was shown to be elevated in PBMCs of patients with cryptococcal meningitis ([@ref7]). Up and down-regulation of ß-arrestin proteins is clearly associated with pathology. Interestingly, disease-associated mutations in either ß-arrestin subtype have, so far, not been found.

Effects of ß-Arrestin on Disease {#sec51}
================================

Inappropriate modulation of cell survival can lead to cancer and fibrotic diseases, while abnormalities in immune cell function have implications for autoimmunity, infection, and the inflammatory component of many diseases. For an in depth review of the role for ß-arrestins in disease, please refer to the work by [@ref80]. Below we present examples of how ß-arrestin modulation of cellular events can become pathophysiological.

Once adhered to human brain endothelial cells, the meningococcus bacterium promotes endothelial cell ß~2~AR-ß-arrestin2 signaling to cSrc-mediated cytoskeletal reorganization ([@ref22]). This delocalizes endothelial junction proteins resulting in destruction of the blood brain barrier tight junctions and enhanced brain infection. Cytoskeletal changes also promote bacterial adhesion to endothelial cells ([@ref22]). ß-arrestin2 also hinders bacterial killing through reducing peripheral blood mononuclear cell cytotoxic activity, decreasing serum levels of interferon-gamma (IFN-γ), an anti-bacterial cytokine, and increasing the serum level of IL-10, an anti-inflammatory cytokine ([@ref7]). Similarly, ß-arrestin2 inhibits the antiviral response by reducing the killing effectiveness of natural killer (NK) cells ([@ref116]). ß-arrestin2 transgenic mice were shown to have higher organ viral loads following murine cytomegalovirus; additionally, NK cells from these mice displayed reduced cytotoxicity. Conversely, ß-arrestin2 knockout mice and their NK cells displayed lower tissue viral titers and enhanced cytotoxicity, respectively.

Studies have also shown that ß-arrestins are involved in the initiation, development, and metastasis of many types of cancer ([@ref92]). In a murine model of chronic myelogenous leukemia, in which mice were transplanted with diseased hematopoietic stem cells, mice devoid of ßarrestin-2 did not succumb to the disease following transplantation of the diseased cells. In contrast, control mice died within 2 months of the transplantation of diseased cells. The study showed ß-arrestin2 promotes signaling *via* the wnt/beta-catenin pathway to promote cancer stem cell maintenance ([@ref33]). Similarly, in a murine model of myelofibrosis, a myeloproliferative neoplasm, mice transplanted with donor ß-arrestin2-KO hematopoietic stem cells infected with a myelofibrosis retrovirus did not develop the disease, whereas controls uniformly succumbed to disease. Abolition of ß-arrestin2-mediated promotion of anti-apoptosis prevented ß-arrestin2-KO cells from repopulating long-term and decreased self-renewal of infected ß-arrestin2-KO cells ([@ref74]).

The role of ß-arrestins in ovarian, prostate, brain, gastric, lung, and breast cancers has been well established ([@ref90]). One study showed ß-arrestin1 could be used as a plasma biomarker to differentiate certain types of lung cancers ([@ref32]). Ovarian cancer metastasis has also been reported to be mediated by ß-arrestin1 ([@ref70]). Studies also suggest ß-arrestin2 as a prognosis marker for colorectal cancer ([@ref76]) and a promoter of lymph node metastasis in non--small cell lung cancer ([@ref20]). Both ß-arrestin1 and 2 have been reported as promoters of prostate cancer albeit through different mechanisms ([@ref45]). Numerous GPCRs and their downstream effectors are envisaged to provide many targets and novel strategies in hepatocellular carcinoma prevention and treatment ([@ref66]). Interestingly, the ß-arrestin biased ß-blocker carvedilol, a ligand that activates ß~2~AR-ß-arrestin2 signaling while inactivating canonical ß~2~AR-Gs signaling, has been found to be beneficial in cancer prevention by virtue of blocking a key step in carcinogenesis, i.e., ERK translocation into the nucleus ([@ref114]; [@ref19]).

Fibrosis is defined as the accumulation of excess extracellular matrix (ECM) components which are mainly derived from fibroblasts and myofibroblasts ([@ref25]; [@ref7]). If highly progressive, the fibrotic process leads to organ malfunction and death ([@ref40]). Renal fibrosis can result in many kidney diseases (diabetic nephropathy, uronephrosis and polycystic kidney) and often leads to chronic kidney disease. ß-arrestin-deficient murine models under unilateral ureteral obstruction show attenuated renal interstitial fibrosis. Moreover, mice and human kidney tissue samples morphologically consistent with nephropathy show increased expression of ß-arrestin1 ([@ref115]). However, it is unknown what receptor is responsible for such a response. Data have implicated AT~1~ receptor-mediated ß-arrestin signaling as responsible for the observed increased extracellular matrix synthesis resulting in renal fibrosis ([@ref112]). Mice with unilateral ureteral obstruction had increased collagen I and fibronectin that correlated with the tubulointerstitial fibrosis and ß-arrestin upregulation. When ß-arrestin signaling was stimulated in a rat renal fibroblast cell line (NRK-49F cells) using \[Sar(1), Ile(4), Ile(8)\] AngII (SII), an AT~1~ receptor ß-arrestin biased ligand, increased collagen I and fibronectin expression was observed, while silencing ß-arrestin expression had the opposite effect ([@ref112]). Expression of ß-arrestin2 is upregulated in liver biopsies from patients with hepatitis B and C, suggesting ß-arrestin2 promotes liver fibrosis ([@ref40]). Taken together, the above data suggest ß-arrestin signaling promotes fibrosis in some tissues such as kidney, liver, heart, and lung ([@ref53]; [@ref40]). These results support the development of G-protein biased ligands that may shut down the pro-fibrotic actions of ß-arrestin in disease.

The range of diseases in which ß-arrestins play a role is very broad. For example, ßarrestin plays a role in brain function. A positive correlation between brain ß-arrestin (ß-arrestin1 and 2) levels (both protein and mRNA) and Alzheimer's disease diagnosis, severity, and amyloid burden has been demonstrated by several investigators ([@ref50]; [@ref99]; [@ref51]). Also, G protein-independent signaling downstream of brain β2AR, delta opioid receptor, and orphan G protein-coupled receptor 3 promote cleavage of amyloid precursor protein (APP) by γ-secretase ([@ref42]) and production of amyloid-β peptide, a defining pathological feature of AD. In a murine model of AD, neurons lacking ß-arrestin2 demonstrate reduced amyloid-ß peptide secretion in culture and detection in the hippocampus and cortex ([@ref99]). In brief, ß-arrestin 2 promotes the pathogenesis of AD through GPCR-initiated regulation of γ-secretase activity, which results in elevated levels of amyloid-ß peptide ([@ref42]). In other cell types, ß-arrestin can have a positive impact on brain function. For example, ß-arrestin2 promotes cofilin translocation to dendritic spines in response to N-methyl-D-aspartic acid (NMDA) receptor activation, and cofilin promotes dendritic spine remodeling which is needed for normal learning and memory ([@ref69]).

There are also examples where the canonical role for ß-arrestins is involved in neuropathophysiology. In Parkinson's disease (PD), a neurodegenerative illness where loss of dopaminergic neurons from the nigrostriatal system affects locomotion, chronic treatment with L-DOPA, a dopamine precursor, induces dyskinesias by D~1~ receptor overactivation ([@ref102]). These abnormal involuntary movements are mediated by Gs signaling as noted by rodent and nonhuman primate models of PD. In ß-arrestin2-KO mice treated with L-DOPA, such movements increased after L-DOPA treatment compared to controls and were prevented after ß-arrestin2 overexpression in both mice and monkeys ([@ref102]). Using PD animal models (rats and macaques), others have demonstrated that using Gs-biased ligands for D~1~ receptors that decrease βarrestin-2 recruitment and associated desensitization of G protein signaling results in sustained locomotive activity ([@ref37]), supporting a canonical role for ß-arrestin in regulating PD dyskinesias.

ß-Arrestin Versus G-Protein Signaling in Disease {#sec50}
================================================

As discussed above, data from the last 2 decades have shown that a single GPCR subtype can couple to different transduction proteins and produce multiple cellular responses. These observations have resulted in a new era of pharmacology where, relative to the endogenous hormone or neurotransmitter, ligands can selectively or at least preferentially activate one of the diverse responses produced by a single GPCR subtype. This phenomenon has been termed "ligand-directed trafficking of receptor stimulus" or "biased signaling." In many cases, the therapeutic effect of a ligand is mediated by one pathway and the adverse effects by another pathway. Thus, rational development of biased ligands has become an active part of modern drug discovery.

To date, the diseases with the most clinical data in support of the development of biased drugs are: the use of ß-adrenergic receptors (ßAR) and angiotensin AT~1~ receptor ligands in congestive heart failure (CHF) ([@ref5]; [@ref55]); μ-opioid receptor (μOR) ligands in the management of pain; and to a lesser extent, possibly ß~2~AR ligands in asthma ([@ref28]; [@ref34]; [@ref43]; [@ref60]). There is also strong preclinical evidence supporting the use of biased ligands for other diseases, such as D~1~ and D~2~ receptor ligands for Parkinson's disease and schizophrenia, respectively ([@ref65]; [@ref37]), sphingosine 1P (S1P) receptor ligands for multiple sclerosis ([@ref27]), and adenosine A~1~ receptor ligands for ischemic heart disease ([@ref4]), among others. It is important to emphasize that neither the canonical signaling pathway associated with the G-protein nor signaling *via* the ß-arrestin-dependent pathway (or any pathway for any receptor) can be termed as universally beneficial or detrimental. The (patho)-physiological effects of any pathway will always be disease-specific, time-dependent, and indeed often cell-specific.

For example, in CHF and asthma, the pathways mediating the beneficial versus adverse effects are currently believed to be the opposite for each disease. In CHF, there are data to support ß-arrestin signaling as anti-apoptotic and cardioprotective ([@ref78]; [@ref16]). This is not only true for ß-arrestin activation by the FDA-approved "ß-blocker," carvedilol, in CHF, but also ß-arrestin activation in other GPCRs such as the angiotensin AT~1~ receptor ([@ref44]; [@ref59]). In CHF, the angiotensin AT~1~ receptor can activate both its canonical G-protein pathway (in this case, Gq) and the ß-arrestin-dependent pathway ([@ref61]; [@ref59]; [@ref97]). Considerable data implicated a clear division between the detrimental effects of AT~1~ receptor signaling via Gq and the protective effect of signaling via ß-arrestin and led to the development of the biased antagonist, TRV-120027 that preferentially inhibits Gq signaling ([@ref8]; [@ref9]). Thus, the ideal ligand profiles for both the ß~2~AR and AT~1~ receptor, when used in CHF, appear to be ligands that antagonize the G-protein pathway (Gs and Gq respectively), and either stimulate, or at least not antagonize the receptor conformation that promotes ß-arrestin-dependent signaling. Perhaps the most compelling evidence for the advantage of this ligand profile as ideal is the observed therapeutic advantage of carvedilol in CHF ([@ref114]). In this regard, it is important to point out a study using a mutated ß~2~AR (ß~2~AR^TYY^) where the mutation renders the ß~2~AR unable to bind G proteins; carvedilol was the only beta-blocker that retained the ability to activate ERK1/2 ([@ref84]). However, more recent findings show that initiation of ERK1/2 activation by ß~2~AR involves a signaling route that is independent of ß-arrestins ([@ref63]). Examination of the role for ß-arrestins in ß~1~AR signaling to ERK1/2 shows that all ERK1/2 signaling downstream of the ß~1~AR requires Gαi protein activation ([@ref111]), including that induced by carvedilol, but that loss of ß-arrestin2 results in reduced ERK1/2 signaling ([@ref30]). Future studies are required before we fully understand how carvedilol's superior clinical efficacy may be related to its unique signaling profile and the role for ß-arrestins. For now, O'Hayre et al. posit that re-interpretation of original findings with respect to the impact of the scaffolding function of ß-arrestins, which may control the localized activation of ERK, versus the ß-arrestin-promoting activation of ERK1/2 may explain some discrepancies ([@ref63]).

In the management of pain, μ opioid receptors (μOR) mediate pain relief through Gi/o activation, while ß-arrestin-dependent signaling induces respiratory depression and constipation ([@ref11]; [@ref72]; [@ref26]; [@ref2]). For example, compared to their wild type controls, ß-arrestin2-KO mice treated with morphine, a μOR agonist, exhibited increased antinociception using a tail-flick and hotplate models of pain ([@ref11]). In addition, the ß-arrestin2-KO mice exhibited less of a reduction in gastrointestinal transit, and no respiratory suppression was observed compared to wild type mice ([@ref72]). These and other findings led to the development of TRV130, also known as oliceridine, a Gi/o-biased ligand ([@ref26]; [@ref2]) for the μOR. Clinical trials using TRV130 for phase II ([@ref106]; [@ref87]) and III studies (APOLLO-1 and -2) have been completed, and while the results are not yet published, TRV-130 displayed greater analgesia and less gastrointestinal and respiratory side effects compared to morphine ([@ref35]). Currently, an open-label safety study is underway (ATHENA trial).

Thus, clinical development of biased ligands is now an active area of research by several pharmaceutical companies and academic laboratories. However, to date, no new chemical entities have made it to FDA-approval, and some have failed in Phase II trials ([@ref64]). While this may cause diminished enthusiasm that pursuing the development of biased ligands may only work theoretically, it is important to emphasize that biased ligands such as carvedilol have already shown superior clinical efficacy ([@ref114]). There are also data showing, famotidine, a histamine H~2~ receptor antagonist used to reduce gastric acid secretion in acid-peptide disorders, may have greater therapeutic efficacy compared to other H~2~ receptor antagonists ([@ref12]). A suggested explanation is that famotidine, besides working as a G protein signaling antagonist by decreasing cAMP, also stabilizes the H~2~ receptor conformation that induces desensitization, likely through ß-arrestin ([@ref1]).

The second generation antipsychotic cariprazine, a dopamine D~2~ and D~3~ receptor partial agonist in most systems, was recently approved for the treatment of schizophrenia and exhibited increased safety and tolerability profiles compared to first generation antipsychotics ([@ref29]). Although not a selective drug, biased signaling towards Gi has been suggested to confer cariprazine with less side effects (i.e. cognitive impairment, hyperprolactinemia, weight gain) ([@ref91]). Conversely, preclinical data also suggest that ß-arrestin biased ligands for the D~2~ receptor can also contribute to schizophrenia treatment by resetting the balance of the excitation inhibition in the prefrontal cortex ([@ref103]). Therefore, both signaling pathways are highly important in the therapeutics for this pathology and reinforce the idea that both targets are equally valuable in drug discovery.

As noted above, some recent attempts to rationally develop biased ligands have failed at various stages of development. However, this should not be interpreted as a failure that biased ligands can be developed. Indeed, one of the major societal and scientific benefits of the pharmaceutical industry's development of dozens of generic drugs for major diseases and symptoms, is that biased ligands have already been developed. For example, the scientific community has already thoroughly screened, using *in vitro* assays, dozens of ß~2~AR and μOR ligands already in clinical use for their activity at several pathways ([@ref114]; [@ref58]; [@ref93]; [@ref105]; [@ref104]); and as described above, other drugs are now retroactively being implicated as being biased ligands as a means of explaining their different therapeutic outcome from other members of the same class of drugs ([@ref114]; [@ref86]; [@ref1]).

To further develop the hypothesis that biased ligands can be rationally designed, it may be useful to view the strategy as not dissimilar from one previously used to produce dozens of therapeutically improved ligands. The last half of the 20^th^ century saw a proliferation of the discovery of receptor subtypes. In many ways, biased ligand synthesis can be viewed as analogous to the development of more receptor subtype selective ligands. The different conformational states that are thermodynamically required to activate different pathways can be viewed in the same way as the different receptor conformations associated with different receptor subtypes.

Alternative or complementary ways to bias GPCR signaling include allosteric modulation of GPCR as well as the use of pepducins and/or nanobodies. Nanobodies, camelid antibody fragments, have been developed that preferentially bind to and stabilize the human ß~2~AR in various conformations ([@ref73]; [@ref95]). Rasmussen et al. produced nanobody 80 (Nb80) that, when bound to receptor, stabilizes the conformation of the receptor producing Gs signaling. Staus *et al* developed four families of nanobodies that stabilized active or inactive ß~2~AR conformations and found biased inhibition of either G protein activation or ß-arrestin recruitment ([@ref94]). They identified Nb60, a negative allosteric nanobody, to modulate and stabilize inactive β2AR state ([@ref95]). As nanobodies can modulate biased ß~2~AR signaling, they can be potential therapeutic agents regulating various pathological processes involving ß~2~AR. Interestingly, Martin et al. synthesized a set of peptidomimetics which are structurally similar to the complementarity-determining region 3 (CDR3) of the nanobody Nb80, and inhibit ß~2~AR-G protein coupling ([@ref57]).

Another approach to biasing receptor signaling involves pepducins, first developed by [@ref23],[@ref24]. Pepducins are the lipid-peptide conjugates with sequences derived from the intracellular loops of the targeted GPCR ([@ref13]). By penetrating cells, pepducins can access receptor conformations not accessible to extracellular ligands that must rely on extracellular receptor binding ([@ref16]). Pepducins regulate the activity of GPCRs by allosteric modulation ([@ref71]). Pepducins for several GPCRs have been reported in the last decade ([@ref23]; [@ref48]; [@ref75]; [@ref96]; [@ref14], [@ref16]). For example, intracellular loop1--9, a ß-arrestin--biased pepducin for the β~2~AR, has been reported to be completely ß-arrestin--biased in primary adult murine cardiomyocytes, possibly enhancing cardioprotective effects for CHF therapy ([@ref16]). Intracellular loops 3--9, a pepducin modulator of G~s~-biased ß~2~AR signaling, has been shown to be a potential asthma therapy candidate as ß-arrestins are believed to be responsible for the symptoms associated with asthma ([@ref109]; [@ref28]; [@ref98]; [@ref14]; [@ref49]). Another G~i~-biased pepducin, ATI-2341, has been developed for the chemokine receptor CXCR4 ([@ref71]). It is noteworthy that successful use of pepducins *in vivo* is currently constrained because pepducins lack a targeting mechanism in multilayered tissues and thus are limited to cells in close proximity to the circulating pepducins ([@ref15]). However, pepducins can potentially share sequences in the intracellular loops of closely-related GPCRs and may have enhanced therapeutic effects mediated by various GPCRs ("polypharmacology") ([@ref13]).

Concluding Remarks {#sec4}
==================

Given the functional versatility of ß-arrestins, they are aptly suited to effectively and broadly regulate cell signaling and resultant physiological and pathophysiological processes. The therapeutic potential of targeting ß-arrestins is enormous, since disease-specific treatments could increase the safety and efficacy of GPCR-targeted therapeutics. On the other hand, given that a single ß-arrestin subtype can modulate dozens of GPCRs, this may pose problems in drug discovery. The search for ß-arrestin modulators will not be easy given the complexity of GPCR signaling pathways and the pleiotropy of ß-arrestin functions making precise targeting of paramount importance. Despite these challenges, there are several ligands preferentially targeting ß-arrestin signaling now in clinical trials and more in development. Thus, we will hopefully soon have answers as to the impact of these ligands in future therapies.
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